Aurora Biomed specializes in advanced laboratory automation technologies that enhance various aspects of genomic and pharmaceutical research. Their offerings include automated liquid handling systems designed to streamline workflows in DNA/RNA microarray spotting, nucleic acid extraction, PCR plate preparation, and next-generation sequencing (NGS) library preparation. The company also provides high-throughput screening platforms for drug discovery, particularly focusing on ion channel and transporter research. Their Ion Channel Reader (ICR) series utilizes atomic absorption spectroscopy combined with a patented microsampling process to accurately measure ion flux in cell-based assays, facilitating the identification of drug interactions and safety assessments early in the drug development process.

In addition to genomic applications, Aurora Biomed's technologies extend to elemental analysis, proteomics, and metabolomics, offering comprehensive solutions for pharmaceutical quality assurance and environmental analysis. Their automated systems are designed to improve efficiency and accuracy in laboratory settings, significantly reducing the time and effort required for repetitive tasks. The company also addresses urgent health needs, such as providing diagnostic test kits and automation solutions for COVID-19 testing, thereby contributing to public health efforts while advancing research capabilities across multiple sectors, including healthcare, agriculture, and food safety.

Canada

Aurora Biomed is committed to supporting life science, drug discovery/safety, and chemical analysis research by providing enabling technologies and services which offer higher throughput while maintaining quality, accuracy, and precision. 

Aurora's product range includes automated liquid-handling workstations, atomic absorption spectrometers, atomic fluorescence spectrometers, microwave digestion systems, and water purification systems.

Aurora Biomed

Company Details